Parkinson’s Disease – Unmet Need – Unmet Need – Levodopa-Induced Dyskinesia (US/EU)
Levodopa-induced dyskinesia (LID) is a complication stemming from the long-term use of levodopa to treat Parkinson’s disease (PD); it causes abnormal involuntary movements. Surveyed neurologists in the United States estimate that more than one in five of their PD patients currently experiences LID, which can be disabling and painful and greatly affect patients’ quality of life and activities of daily living. Only a few options are available to treat PD–LID, including amantadine IR, a long-standing generic drug that is not specifically approved for LID and has an unfavorable side-effect profile. In the United States, Supernus’s Gocovri (amantadine ER) is the only FDA-approved treatment for PD–LID. Research suggests that Supernus’s Xadago has antiglutamatergic properties that may positively impact LID. In addition, newly launched levodopa formulations (e.g., AbbVie’s Vyalev, Amneal’s Crexont) may prove effective in minimizing the emergence of LID. Understanding prescriber perceptions of the available options for PD–LID and the drivers behind prescribers’ clinical decision-making for the indication can help drug developers identify levers for new product positioning and differentiation.
QUESTIONS ANSWERED
- What clinical endpoints and drug attributes are most influential in prescribing for PD–LID? How do neurologists rate the performance of amantadine, Gocovri, Xadago, and Vyalev on these attributes?
- What are the prevailing areas of unmet need and opportunity in the treatment of PD–LID?
- Based on conjoint analysis and TPP simulation, what trade-offs among efficacy, safety, and price are neurologists willing to make for a hypothetical new drug for PD–LID?
PRODUCT DESCRIPTION
- Evaluate clinical and nonclinical product attributes that influence treatment decisions through physicians’ weightings and analysis of stated vs. derived importance.
- Pinpoint areas of high unmet need by assessing current drug performance against key attributes and treatment drivers.
- Analyze market scenarios for different target product profiles using the TPP Simulator.
Markets covered: United States, United Kingdom, France, Germany
Primary research: Survey of 61 U.S. and 31 European neurologists fielded in January 2025
Key drugs: amantadine IR, Xadago, Gocovri, Crexont, Vyalev
Key feature: Target Product Profile (TPP) simulator tool allows for customizable market simulations based on conjoint analysis. Compare up to seven TPPs across multiple disease-specific attributes and price points to gauge which variables influence prescribing behavior.
